Research interests in targeting IL-6R have shown clinical efficacy in various inflammatory diseases (Rosenberg et al., 2023; Sarfraz et al., 2021; Hossein Heydari et al., 2023; Østergaard et al., 2023; Pugliesi et al., 2023); however, its role in liver fibrosis remains complex and not fully elucidated. The gene discussed is IL6R; the disease is Hepatic fibrosis.